Abstract P2-01-16: Pharmacogenomic variants and risk of adverse events in breast cancer patients treated with Trastuzumab-deruxtecan: results from the PROCURE project
Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Cristina Rodríguez‐Antona(Instituto de Salud Carlos III), Isabel Gallegos, Carmen Hinojo, Juan Miguel Cejalvo(Universitat de València), Ana Milena Vargas, María José Echarri, Blanca Cantos(Hospital Universitario Puerta de Hierro Majadahonda), Sònia Pernas, Guillermo Villacampa(Vall d'Hebron Institut de Recerca), Tomás Pascual(Breast Cancer Research Foundation), Javier Cortés(Villa Maria Hospital), Javier de Nicolás‐Hernández, Virginia Martínez, María Cobos-Fernández(Hospital Universitario 12 De Octubre), Coralia Bueno(Hospital Universitario Fundación Alcorcón), Alicia Arenas(Universidad de Sevilla), Santiago Escrivá-de-Romaní(Unknown), Teresa Curiel(Instituto de Investigación Sanitaria de Santiago), Elisenda Llabrés, Eva Ciruelos(Hospital Universitario 12 De Octubre), Cristina Saura(Vall d'Hebron Hospital Universitari), Laia Joval-Ramentol, Bartomeu Fullana, Carlos Valdivia, Josefina Cruz(Hospital Universitario de Canarias), Maria Gion, Alejandro Falcón(Princess Margaret Cancer Centre), Alfonso López de(Hospital Clínico San Carlos), María Vidal(Inserm)
Cited by 3
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k